The U.S. Meibomian Gland Dysfunction (MGD) market consists of products used for diagnosis and treatment of MGD. MGD occurs when the meibomian glands in the eyelid produce an abnormal composition of the tear film. Some key products in this market include ocular lubricants or artificial tears containing lipid complexes that help replenish the tear film and eyelid cleansers or warm compresses that help clear the blocked glands. MGD is a common condition that causes symptoms like dry eyes, itchiness and blurred vision. Growing awareness about eye care and risks of untreated MGD is driving more people to seek diagnosis and treatment, thereby spurring market growth.

The U.S. Meibomian Gland Dysfunction Market is estimated to be valued at US$ 4059.13 Mn in 2024 and is expected to exhibit a CAGR of 15.% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the U.S. Meibomian Gland Dysfunction are Pfizer, Inc., AbbVie Inc., Johnson and Johnson Vision Care Inc., Bausch Health Companies Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., I-MED Pharma Inc., OASIS Medical, Sentiss Pharma Pvt. Ltd., RegeneRx, Akorn, Inc. AFT Pharmaceuticals, Alcon Inc. Major players are focusing on expanding their product portfolios by developing new drug delivery systems and launching combination therapies.

The increasing awareness about symptoms and management of MGD presents significant growth opportunities for players. Companies are investing in educating eye care professionals as well as consumers to recognize MGD symptoms early.

Globally, North America dominates the MGD market due to high adoption of new treatment options. However, Asia Pacific is expected to witness fastest growth owing to growing eye care infrastructure and rising disposable incomes in the region. Many international players are also expanding their distribution networks in Asia Pacific and Latin American countries.

Market drivers

One of the key drivers of the U.S. Meibomian Gland Dysfunction Market Demand is the growing geriatric population susceptible to MGD. Around 50% of people over 60 years suffer from some form of MGD due to weakening of meibomian glands with age. As life expectancy increases, prevalence of MGD and corresponding demand for management products will continue rising. Growing awareness about benefits of early MGD treatment through social media and eye care professional recommendations is also boosting the market growth.

Get More Insights on- U.S. Meibomian Gland Dysfunction Market

For Deeper Insights, Find the Report in the Language that You want:

• French
• German
• Italian
• Russian
• Japanese
• Chinese
• Korean
• Portuguese

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)